The Massachusetts Life Sciences Center’s mission is to serve as the hub of the world’s life sciences ecosystem, encourage innovation through investments in good science and business, strengthen and protect Massachusetts’ global leadership position in the life sciences, accelerate the commercialization of promising treatments, therapies, and cures that will improve patient care, create jobs, drive economic development and STEM workforce development.
Lead the industry’s next frontier.
See funding opportunities.
News and Breakthroughs
Interns Playing a Vital Role in a Pandemic
Kephera Diagnostics was uniquely positioned to pivot their current pipeline of infectious disease diagnostics from Lyme disease and Zika to focus their attention on COVID-19. To help with the research and speed up the development of the COVID-19 test, the company hired two interns through the MLSC’s Internship Challenge.
MetroWest Manufacturer Pivoting to Support COVID-19 Research
Governor Baker and Massachusetts Senate President Karen Spilka toured MatTek Life Sciences, a current participant in the Manufacturing Emergency Response Team (M-ERT). The company is transitioning from the manufacture of cell culture media to the production of viral transport media.
MLSC part of “unprecedented collaboration” to combat COVID-19
Recognizing the multi-institutional initiative’s ability to bring together leading scientists and researchers from across the Commonwealth, the MLSC is providing up to $2.3 million to support collaborative projects through the Massachusetts Consortium on Pathogen Readiness, convened by Harvard Medical School.
#1 life sciences ecosystem in the world.
Massachusetts is home to the most verdant and productive life sciences ecosystem in the world. With industry, academia, and government working together, a burgeoning economy has flourished to develop the finest talent pipeline and a hotbed for great science, great inventions, and great leaders to propel the development of new therapies, devices, and scientific advancements that are improving patient health and well-being in Massachusetts and around the world.
- in talent with the highest percentage of residents who hold undergraduate degrees.
- of the top 20 biopharma companies.
- of K-12 students in Massachusetts learn with equipment funded by MLSC.
Strengthening networked connections. Fortifying diversity of talent.
The MLSC’s prioritized commitment to talent development and a more diverse workforce is at the core of how we fulfill our mission. Our strategy starts at the youngest generation, sparking a passion for STEM by supplying middle school and high school level students with the equipment and trained professionals to compete with their peers. We capitalize on the abundance of small and medium life science companies by providing paid internship opportunities. We are also home to the highest density of leading academic research and medical institutions in the country.
LEAH Knox Scholars: Making Experiences for Young Scientists
The program provided the cohort with more than 40 hours of pre-lab placement orientation, leadership, team building and career and college readiness workshops, alongside 130 hours of learning basic lab skills.
COVID-19 Workforce Training Funds
In an effort to help manufacturers during COVID-19, $1 million for workforce training grants was made available through M-ERT funding.
Our workforce development program facilitates and funds paid internship opportunities focused on enhancing the talent pipeline for Massachusetts life sciences companies. The experiential learning opportunities create a pathways to successful careers.
Investing in infrastructure. Orienting for innovation.
The MLSC is committed to fortifying the innovation ready-infrastructure of the future by fostering robust life sciences development in women’s health, big data, and advanced manufacturing from an early-stage life science company to a world-renowned institution. Our researchers, entrepreneurs, and members of our life sciences ecosystem have access to cutting-edge laboratory equipment and analysis in every corner of the state.
MLSC provided a $5 million grant to fund a new re source for the industry and the local bio-economy, including a life sciences laboratory focused on scale-up biomanufacturing comprising nearly 100,000 square feet.
COVID-19 Manufacturing Emergency Funding
This $10 million initiative aids manufacturing efforts to produce PPE and other critical devices for health care workers on the frontlines of the COVID-19 pandemic.
Institute for Applied Life Sciences
A division of UMass Amherst, IALS focuses on state-of-the-art wearable devices, biomolecule delivery vehicle combinations, discovering novel disease-related cell pathways, drug-targets, and therapeutics.
Fostering seed-stage companies. Scaling growing businesses.
Investments to fund and accelerate inventive concepts from early-stage companies is at the core of the Center’s overall portfolio strategy. For companies looking to scale their business or relocate to Massachusetts, the MLSC will make a concentrated effort to provide the strategic insights, tax incentives, grants, or loans to qualifying companies, creating a burgeoning economy and job market.
LivOnyx: Can you kill a pathogen in three seconds?
The COVID-19 pandemic has placed a hyper-focus on hygiene and infection prevention. For LivOnyx, and its President and Co-Founder Carmela Mascio, that focus is at the heart of its mission.
Abiomed, a Tax Incentive awardee, has grown from 350 employees to 1,300 worldwide in eleven years. The company has doubled its footprint from 60,000 to 120,000 square feet in Danvers.
COVID-19 Resources for Businesses
The Baker-Polito Administration is committed to partnering with the business community to navigate the outbreak of COVID-19. The Administration’s goal is to offer the best information in this evolving economic crisis.
Cultivating emerging research. Steering emerging inventions.
Massachusetts Life Sciences Center is deliberate with its offering of portfolio programs to evolve as the industry does and invest in the research and development, commercialization and manufacturing, people, and regions that need it most.
A new initiative designed to improve the discovery, technical innovation, and analysis of datasets to answer pressing life science questions around women’s health and to recognize gender differences in research.
Life Science Cares COVID-19 Response Fund
Life Science Cares (LSC) organizes biopharma executives and employees to fight poverty in the community. LSC launched the COVID-19 Response Fund on March 18 and has raised more than $1 million to date.
Catalyzing Biomanufacturing Innovation
As the development of new innovative therapeutic treatments continues, future products can benefit from biomanufacturing innovation to reduce costs and avoid drug shortages